arrow
D

David Hwang

us food & drug administration (fda)
H指数:55
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Significance of Spread Through Airspaces (STAS) in Stage Ia/bN0 Non-small Cell Lung Cancer – An Evaluation in the JCOG0802/WJOG4607L Clinical Trial Patients

Stage Ia/bN0非小细胞肺癌中通过气腔扩散(STAS)的预后意义——JCOG0802/WJOG4607L临床试验患者的评估

2026-08-140
PRE
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer

分子肿瘤委员会:国际肺癌研究协会的共识声明

2025-07-070
PRE
Lung Transplant Immunomodulation with Genetically Engineered Mesenchymal Stromal Cells-Therapeutic Window for Interleukin-10
CELLS
IF5.2
2024-05-172
OAAI
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies
2024-04-1614
OA
Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study
2024-01-014
OAAI
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies

程序性细胞死亡蛋白1抑制剂和MET靶向治疗在MET外显子14跳跃突变的NSCLC中的疗效和毒性: 序贯治疗

2023-10-016
OA
Prognostic implications of and clinical risk factors for acute lung injury and organizing pneumonia after lung transplantation: Data from a multicenter prospective cohort study

肺移植后急性肺损伤和组织肺炎的预后意义和临床危险因素: 来自多中心前瞻性队列研究的数据

2022-12-017
OA